3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Recurrence
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Prostate Cancer Recurrent
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Blast Crisis
1
Interventions
Temozolomide
16
Irinotecan
13
Cyclophosphamide
11
dinutuximab
9
naxitamab
7
Vincristine
7
Carboplatin
6
sargramostim
5
Melphalan
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Etoposide
5
fludarabine
4
Topotecan
4
Thiotepa
4
Eflornithine
4
Doxorubicin
4
Cisplatin
4
etoposide phosphate
3
Zoledronic Acid
3
Specimen Handling
3
Isotretinoin
3
Granulocyte Colony-Stimulating Factor
3
saponin QA-21V1
2
lutetium Lu 177 dotatate
2
aldesleukin
2
Vorinostat
2
Stem Cell Transplantation
2
Radiation
2
Platinum
2
Mesna
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroblastoma
×
Dasatinib
×
Clear all
NCT02559778
2026-04-28
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2
Recruiting
500 enrolled